SK5962002A3 - Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist - Google Patents

Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist Download PDF

Info

Publication number: SK5962002A3
Authority: SK; Slovakia
Prior art keywords: compound; sodium; dimethoxyphenyl; ethoxy; diphenylpropionate
Prior art date: 1999-10-27

Application number

SK596-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Rolf Jansen

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-27

Filing date

2000-10-17

Publication date

2002-09-10

2000-10-17 Application filed by Basf Ag filed Critical Basf Ag

2002-09-10 Publication of SK5962002A3 publication Critical patent/SK5962002A3/sk

Links

239000002308 endothelin receptor antagonist Substances 0.000 title abstract description 6
HTRPIHRNVLLBGC-UHFFFAOYSA-M sodium;3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylpropanoate Chemical compound [Na+].C1=C(OC)C(OC)=CC=C1CCOC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C([O-])=O)OC1=NC(C)=CC(C)=N1 HTRPIHRNVLLBGC-UHFFFAOYSA-M 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 18
239000007787 solid Substances 0.000 claims abstract description 6
208000006673 asthma Diseases 0.000 claims description 7
238000000034 method Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 2
239000013543 active substance Substances 0.000 claims 1
229940118365 Endothelin receptor antagonist Drugs 0.000 abstract description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
-1 sodium alkoxides Chemical class 0.000 description 3
239000003826 tablet Substances 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010020852 Hypertonia Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
231100000284 endotoxic Toxicity 0.000 description 1
230000002346 endotoxic effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Oncology (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK596-2002A 1999-10-27 2000-10-17 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist SK5962002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19951671A DE19951671A1 (de)	1999-10-27	1999-10-27	2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
PCT/EP2000/010202 WO2001030767A1 (de)	1999-10-27	2000-10-17	2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionsäure-natriumsalz und seine verwendung als endothelinantagonist

Publications (1)

Publication Number	Publication Date
SK5962002A3 true SK5962002A3 (en)	2002-09-10

Family

ID=7927001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK596-2002A SK5962002A3 (en)	1999-10-27	2000-10-17	Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4- dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist

Country Status (17)

Country	Link
EP (1)	EP1228047A1 (cs)
JP (1)	JP2003512460A (cs)
KR (1)	KR20020047301A (cs)
CN (1)	CN1384822A (cs)
AU (1)	AU1272701A (cs)
BG (1)	BG106700A (cs)
BR (1)	BR0015112A (cs)
CA (1)	CA2389012A1 (cs)
CZ (1)	CZ20021485A3 (cs)
DE (1)	DE19951671A1 (cs)
HU (1)	HUP0203476A3 (cs)
IL (1)	IL149312A0 (cs)
MX (1)	MXPA02004071A (cs)
NO (1)	NO20021986L (cs)
SK (1)	SK5962002A3 (cs)
TR (1)	TR200201169T2 (cs)
WO (1)	WO2001030767A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2881078C (en)	2004-06-24	2018-10-02	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19636046A1 (de) *	1996-09-05	1998-03-12	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

1999
- 1999-10-27 DE DE19951671A patent/DE19951671A1/de not_active Withdrawn
2000
- 2000-10-17 IL IL14931200A patent/IL149312A0/xx unknown
- 2000-10-17 SK SK596-2002A patent/SK5962002A3/sk unknown
- 2000-10-17 HU HU0203476A patent/HUP0203476A3/hu unknown
- 2000-10-17 MX MXPA02004071A patent/MXPA02004071A/es unknown
- 2000-10-17 JP JP2001533121A patent/JP2003512460A/ja not_active Abandoned
- 2000-10-17 CN CN00814871A patent/CN1384822A/zh active Pending
- 2000-10-17 TR TR2002/01169T patent/TR200201169T2/xx unknown
- 2000-10-17 WO PCT/EP2000/010202 patent/WO2001030767A1/de not_active Ceased
- 2000-10-17 CZ CZ20021485A patent/CZ20021485A3/cs unknown
- 2000-10-17 CA CA002389012A patent/CA2389012A1/en not_active Abandoned
- 2000-10-17 AU AU12727/01A patent/AU1272701A/en not_active Abandoned
- 2000-10-17 KR KR1020027005457A patent/KR20020047301A/ko not_active Ceased
- 2000-10-17 EP EP00974404A patent/EP1228047A1/de not_active Withdrawn
- 2000-10-17 BR BR0015112-2A patent/BR0015112A/pt not_active IP Right Cessation
2002
- 2002-04-26 NO NO20021986A patent/NO20021986L/no not_active Application Discontinuation
- 2002-05-14 BG BG106700A patent/BG106700A/xx unknown

Also Published As

Publication number	Publication date
AU1272701A (en)	2001-05-08
HUP0203476A2 (en)	2003-05-28
MXPA02004071A (es)	2002-10-11
WO2001030767A1 (de)	2001-05-03
IL149312A0 (en)	2002-11-10
CN1384822A (zh)	2002-12-11
KR20020047301A (ko)	2002-06-21
BG106700A (en)	2003-02-28
EP1228047A1 (de)	2002-08-07
BR0015112A (pt)	2002-10-29
NO20021986D0 (no)	2002-04-26
TR200201169T2 (tr)	2002-09-23
NO20021986L (no)	2002-04-26
CA2389012A1 (en)	2001-05-03
HUP0203476A3 (en)	2003-07-28
DE19951671A1 (de)	2001-05-03
JP2003512460A (ja)	2003-04-02
CZ20021485A3 (cs)	2003-06-18

Publication	Publication Date	Title
US7087597B1 (en)	2006-08-08	Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
ES2211965T3 (es)	2004-07-16	Quinolonas y su utilizacion terapeutica.
KR101221864B1 (ko)	2013-01-14	4-［［(7ｒ)-8-사이클로펜틸-7-에틸-5,6,7,8-테트라하이드로-5-메틸-6-옥소-2-프테리디닐］아미노］-3-메톡시-ｎ-(1-메틸-4-피페리디닐)벤즈아미드의 수화물 및 다형체, 이들의 제조방법, 및 약제로서의 이들의 용도
EP3412660B9 (en)	2021-04-14	Sulfonamide derivative and pharmaceutical composition containing same
US20040132732A1 (en)	2004-07-08	Quinazolinones and derivatives thereof as factor Xa inhibitors
JP2021504310A (ja)	2021-02-15	血漿カリクレイン阻害剤及びその塩の固体形態
SK122094A3 (en)	1995-05-10	Perhydrisoindole derivatives and their preparation and pharmaceutical agents which contains these derivatives
JP2000504315A (ja)	2000-04-11	ブラジキニン受容体親和性を有する新規ｎ―（アリールスルホニル）アミノ酸誘導体
EP0769007A1 (en)	1997-04-23	2-ureido-benzamide derivatives
KR100300566B1 (ko)	2001-11-22	피리미디논유도체와그의제조방법및용도
CN117642396A (zh)	2024-03-01	αVβ6和αVβ1整联蛋白抑制剂及其用途
CA2033363A1 (en)	1991-07-03	Quinazoline derivatives and their preparation
CN110891939A (zh)	2020-03-17	苯并氮杂卓衍生物
NZ554469A (en)	2010-02-26	Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
US20050043304A1 (en)	2005-02-24	Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
WO2013106756A2 (en)	2013-07-18	Antimicrobial agents
MXPA02000033A (es)	2002-07-02	Polimorfos de un diclorhidrato cristalino de azobiciclo (2, 2, 2)oct-3-ilamina y sus composiciones farmaceuticas.
SK39097A3 (en)	1998-08-05	Bicyclic amidine derivatives useful in therapy
CN118063489B (zh)	2025-11-18	吴茱萸碱类化合物及其制药用途
US7122560B2 (en)	2006-10-17	Lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
US6407256B1 (en)	2002-06-18	Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
OA11956A (en)	2006-04-13	Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions.
CA2389012A1 (en)	2001-05-03	Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist
KR20010101440A (ko)	2001-11-14	대뇌 허혈의 예방 및 치료를 위한 2-치환된1,2-벤즈이소티아졸 유도체 및 3-치환된테트라히드로피리도피리미디논 유도체의 용도
US20020049320A1 (en)	2002-04-25	6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof